TRPV1 and obesity due to melanocortin 4 receptor deficiency: The clinically safe TRPV1 antagonist XEN-D0501 is currently under development as an oral drug for overactive bladder (148); undoubtedly, these findings provide valuable clinical data for the development of TRPV1-targeted drugs to treat obesity.